Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972

Lilly makes one if its biggest acquisitions in recent years to acquire orexin-based therapies for sleep disorders, an area that is seeing intense development activity with multiple potential entrants set to enter the fray.

For $5.6bn, Biogen will add Empaveli and Syfovre to its portfolio, but more important may be how Apellis’s experience with Empaveli can benefit Biogen’s hopes for felzartamab.

Measles outbreaks in young children in the US and UK have occurred in the face of antivax sentiment. But a federal judge’s ruling against the ACIP’s reformation and its actions and a meningitis outbreak in young adults in the UK may be enough to sway the tide.

The drugmaker presented positive efficacy and safety data from the CORALreef AddOn trial at the American College of Cardiology meeting for the oral PCSK9 inhibitor added to statins.

The next-gen hypophosphatasia treatment failed to reach significance in adult-onset patients, but AstraZeneca will hope regulators approve it across all patient groups as a successor to Strensiq.